HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
David J TunnicliffeSuetonia C PalmerBrydee A CashmoreValeria M SaglimbeneRathika KrishnasamyKelly LambertDavid W JohnsonJonathan C CraigGiovanni Fm StrippoliPublished in: The Cochrane database of systematic reviews (2023)
Statins reduce death and major cardiovascular events by about 20% and probably make no difference to stroke or kidney failure in people with CKD not requiring dialysis. However, due to limited reporting, the effect of statins on elevated creatinine kinase or rhabdomyolysis is unclear. Statins have an important role in the primary prevention of cardiovascular events and death in people who have CKD and do not require dialysis. Editorial note: This is a living systematic review. We will search for new evidence every three months and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
Keyphrases
- cardiovascular events
- chronic kidney disease
- cardiovascular disease
- end stage renal disease
- systematic review
- coronary artery disease
- meta analyses
- current status
- type diabetes
- acute kidney injury
- adverse drug
- atrial fibrillation
- peritoneal dialysis
- randomized controlled trial
- metabolic syndrome
- emergency department
- uric acid
- tyrosine kinase